Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as fruquintinib
fruquintinib+sintilimab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| fruquintinib+sintilimab | DRUG | fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle. |
| axitinib / everolimus | DRUG | axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle. |
| fruquintinib | DRUG | fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle. |
Fruquintinib is an investigational small molecule kinase inhibitor being developed for oncology indications including colorectal cancer, gastric cancer, advanced renal cell carcinoma, and metastatic colorectal cancer. It is also being studied for drug-drug interactions and food effects in healthy subjects. The drug is not FDA approved and remains in clinical development.
Fruquintinib is a small molecule kinase inhibitor, belonging to the -tinib class of targeted therapies. It works by inhibiting kinase enzymes involved in tumor growth and angiogenesis. The drug is being studied across multiple cancer types, including colorectal and gastric cancers, where kinase signaling pathways are frequently dysregulated.
Fruquintinib is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed under the ticker HCM. The company is conducting clinical trials of the drug primarily in China across multiple oncology indications, including colorectal cancer and gastric cancer.
Fruquintinib is in Phase 1 clinical development, though completed trials have included Phase 2 and Phase 3 studies. The drug has received FDA designations of Priority Review and Breakthrough Therapy. It remains investigational and is not yet FDA approved for any indication.
Fruquintinib has been studied in several clinical trials, including NCT01975077 (Phase Ib in 3rd line metastatic colorectal cancer), NCT02196688 (Phase 2 in metastatic colorectal cancer), NCT02314819 (Phase 3 FRESCO trial in 3+ line colorectal cancer), and NCT03223376 (Phase 3 FRUTIGA trial in second line gastric cancer). These trials have been completed.
Fruquintinib is known by its generic name and does not have alternative names listed in the available data. It is a distinct small molecule kinase inhibitor being developed by HUTCHMED for multiple oncology indications, including colorectal cancer and gastric cancer.